{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:52Z","timestamp":1793037652146,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Exon 18 delE709_T710insD is an extremely rare mutation in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this mutation remains unclear. In this case report, we report a case of NSCLC harboring EGFR exon 18 delE709_T710insD that was not detected by a commercially available assay, but was detected by a next-generation sequencing cancer panel. A 56-year old female patient with advanced NSCLC was diagnosed as EGFR-mutation-negative using the PNAClamp method. ALK rearrangement was also absent and she received cytotoxic chemotherapies. Clinical characteristics, including adenocarcinoma histology and no history of smoking, implied the presence of a driver mutation, so a next-generation-sequencing Oncomine\u00ae Cancer Research Panel was conducted in the patient\u2019s clinical course and the EGFR exon 18 delE709_T710insD mutation was detected. The patient started afatinib as sixth-line treatment and her pulmonary lesion significantly decreased in size. Afatinib was continued for 7 months until disease progressed.<\/jats:p>","DOI":"10.1093\/jjco\/hyz086","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:21:49Z","timestamp":1558610509000},"page":"786-788","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation"],"prefix":"10.1093","volume":"49","author":[{"given":"Yoshitaka","family":"Iwamoto","sequence":"first","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Nakasuka","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Umeno","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Hirabae","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[{"name":"Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"2019090612551706400_hyz086C1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2019090612551706400_hyz086C2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"2019090612551706400_hyz086C3","doi-asserted-by":"crossref","first-page":"38789","DOI":"10.18632\/oncotarget.5887","article-title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer","volume":"6","author":"Hirano","year":"2015","journal-title":"Oncotarget"},{"key":"2019090612551706400_hyz086C4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/2159-8290.CD-15-0654","article-title":"EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib","volume":"5","author":"Gallant","year":"2015","journal-title":"Cancer Discov"},{"key":"2019090612551706400_hyz086C5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/2159-8290.CD-16-0075","article-title":"EGFR fusions as novel therapeutic targets in lung cancer","volume":"6","author":"Konduri","year":"2016","journal-title":"Cancer Discov"},{"key":"2019090612551706400_hyz086C6"},{"key":"2019090612551706400_hyz086C7","doi-asserted-by":"crossref","first-page":"eaan6566","DOI":"10.1126\/scitranslmed.aan6566","article-title":"A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer","volume":"9","author":"Kohsaka","year":"2017","journal-title":"Sci Transl Med"},{"key":"2019090612551706400_hyz086C8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"2019090612551706400_hyz086C9","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.2147\/OTT.S118071","article-title":"Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer","volume":"9","author":"Wu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2019090612551706400_hyz086C10","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/JTO.0b013e3182635ab4","article-title":"EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer","volume":"7","author":"Ackerman","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2019090612551706400_hyz086C11","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-15-1046","article-title":"EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs","volume":"21","author":"Kobayashi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2019090612551706400_hyz086C12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2017.02.023","article-title":"EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib","volume":"108","author":"Ibrahim","year":"2017","journal-title":"Lung Cancer"},{"key":"2019090612551706400_hyz086C13","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.jtho.2018.01.006","article-title":"EGFR exon 18 delE709_T710insD as an acquired resistance mechanism to afatinib in an advanced EGFR exon 18 E709H lung adenocarcinoma","volume":"13","author":"Zeng","year":"2018","journal-title":"J Thorac Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyz086\/28795842\/hyz086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/8\/786\/29738587\/hyz086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T16:55:34Z","timestamp":1567788934000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/49\/8\/786\/5514164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,6,12]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz086","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,6,12]]}}}